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EdemaAlthough there is evidence for the anti-inﬂammatory activity of nicotinamide, there is no evaluation of its
effects in models of nociceptive and inﬂammatory pain. In addition, there is no information about the
potential anti-inﬂammatory and antinociceptive activities of the nicotinamide isomers, picolinamide and
isonicotinamide. Per os (p.o.) administration of nicotinamide (1000 mg/kg, −1 h) inhibited the ﬁrst and
second phases of the nociceptive response induced by formalin in mice. In the model of nociceptive pain,
exposure of mice to a hot-plate (50 °C), nicotinamide (1000 mg/kg, −1 h) also presented antinociceptive
activity. Nicotinamide (500 mg/kg, −1 and 3 h) also inhibited the mechanical allodynia induced by
carrageenan in rats, a model of inﬂammatory pain. In addition to inhibiting the nociceptive response,
nicotinamide (500 or 1000 mg/kg,−1 and 3 h) inhibited the paw edema induced by carrageenan in mice and
rats. P.o. administration of picolinamide (125 mg/kg,−1 h) and isonicotinamide (500 or 1000 mg/kg,−1 h)
inhibited the second phase of the nociceptive response induced by formalin in mice. The paw edema induced
by carrageenan in mice was also inhibited by isonicotinamide (500 or 1000 mg/kg, −1 h) and picolinamide
(125 mg/kg, −1 h and 3 h). The results represent the ﬁrst demonstration of the activity of nicotinamide and
its isomers in models of nociceptive and inﬂammatory pain and provide support to their anti-inﬂammatory
activity. The demonstration of new activities for nicotinamide is important as it may contribute to expand its
use in the treatment of other pathological conditions.Coelho).
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Nicotinamide is useful to prevent or treat pellagra, a disease
characterized by diarrhea, dementia and dermatitis (Hegyi et al.,
2004). However, there are many studies clearly showing that
nicotinamide also has other functions. It has been shown to protect
rat pancreatic beta cells exposed to streptozotocin or hydrogenperoxide
(Hoorens and Pipeleers, 1999) and prevent streptozotocin-induced
diabetes in rats (Junod et al., 1969). Some studies have also
demonstrated the anti-inﬂammatory activity of nicotinamide in
experimentalmodels of arthritis inducedbypotassiumperoxochromate
inmice (Miesel et al., 1995) and pleurisy induced by carrageenan in rats
(Cuzzocrea et al., 1999b). The efﬁcacy of nicotinamide in models of
traumatic brain injury was also reported (Hoane et al., 2003, 2006a,
2006b). In addition to its anti-inﬂammatory activity in experimental
models, nicotinamidehas alsobeen shown to induce beneﬁcial effects in
patients with rheumatoid arthritis (Hoffer, 1959).
Although the mechanisms that contribute to these activities of
nicotinamide are not clear, it is possible that inhibition of poly(ADP-ribose) polymerase-1 (PARP-1) may have an important role (Radons
et al., 1994; Uchigata et al., 1982; Virág and Szabó, 2002). This enzyme
transfers adenosine diphosphate-ribose units from nicotinamide ade-
nine dinucleotide (NAD+) to many nuclear proteins. Although such
activity is important tomany processes including gene expression, DNA
repair and apoptosis, excessive activation of PARP-1 is implicated in the
development of inﬂammatory conditions (Hassa and Hottiger, 2002;
Szabó, 1998). Excessive activation of PARP-1 may result in marked
reduction of NAD+ content, leading to energy depletion, dysfunction
and cell death (Giansanti et al., 2010; Szabó, 1998). Direct evidence
supporting the inﬂammatory role of PARP-1 has been derived from
studies in which a reduced inﬂammatory response was observed in
animals deﬁcient of this enzyme or treated with pharmacological
inhibitors (Cuzzocrea et al., 1999a, 1999b; Szabó, 1998).
Nicotinamide, a PARP-1 inhibitor and a precursor of NAD+,
maintains the concentrations of this coenzyme and may prevent
cellular alterations resulting from excessive activation of PARP-1
(Uchigata et al., 1982). Although there is evidence for the anti-
inﬂammatory activity of the nicotinamide, derived mainly from in
vitro studies, few studies investigated its effect in in vivo models of
inﬂammation (Cuzzocrea et al., 1999a, 1999b; Miesel et al., 1995).
Regarding the effect in experimental models of pain, nicotinamide
reverses the mechanical and thermal hyperalgesia in streptozotocin
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effect induced by nicotinamide in models of nociceptive and
inﬂammatory pain has not been investigated. In addition, there is
no information about the potential anti-inﬂammatory and antinoci-
ceptive activities of its isomers, picolinamide and isonicotinamide,
although both inhibit the activity of PARP-1 (Grifﬁn et al., 1995) and
the late increases the activity of silent information regulator 2 (Sauve
et al., 2005), a NAD+-dependent histone deacetylase that has been
suggested to present both anti- and pro-inﬂammatory activities (Gallí
et al., 2011).
Thus,we aimed to investigate the effects induced by nicotinamide in
experimental models of nociceptive and inﬂammatory pain and
inﬂammatory edema, in order to provide further information that
may contribute to expand its use in the treatment of painful or inﬂam-
matory conditions. The rationale to investigate the effects induced by
the two nicotinamide isomers, picolinamide and isonicotinamide
(Fig. 1), is underscored by the fact that both also inhibit PARP-1 (Itoh
et al., 1984;Uchigata et al., 1982) and there is not any information about
their potential anti-inﬂammatory and antinociceptive activities.
2. Materials and methods
2.1. Animals
Female Swiss mice (24–28 g) and female Wistar rats (200–250 g)
were used. The animals had free access to food and water and were
maintained in a room with a 12 h light-dark cycle for at least 3 days
before the experiment to allow acclimatization. The experiments
were carried out at a room temperature of 27 °C. This temperature
was used because the thermoneutral zone for mice and rats ranges
between 26 and 34 °C, a temperature range thatmarkedly differs from
that of standard laboratory environments which could be stressful
and affect many aspects of physiology and behavior (Gaskill et al.,
2009; Gordon, 1990). All experiments were conducted according to
the ethical guidelines for investigation of experimental pain in
conscious animals (Zimmermann, 1983) and approved by the Ethics
Committee on Animal Experimentation of the Federal University of
Minas Gerais.
2.2. Drugs
Nicotinamide (Sigma,USA), isonicotinamide (Sigma-Aldrich, France),
picolinamide (Sigma-Aldrich, Germany), λ-carrageenan (Sigma, USA),
formaldehyde 37% m/v (Sigma, USA), dipyrone (Sanoﬁ Aventis, Brazil),
phenobarbital (Aventis Pharma, Brasil) and carboxymethylcellulose
sodium salt (Sigma, USA) were used. The suspensions were prepared
in 0.5% of carboxymethylcellulose sodium salt suspension in saline
immediately before the experiments. The volume of per os (p.o.)
administration was 12 ml/kg either for mice or rats.
2.3. Evaluation of the nociceptive response induced by formalin in mice
Formalin (2.5%, 20 μl) was injected via the subcutaneous (s.c.)
route into the dorsum of the right hind paw of mice 1 h after p.o.Fig. 1. Chemical structures of nicotinamide and its isomers, picolinamide and
isonicotinamide.administration of nicotinamide, isonicotinamide or picolinamide.
Each mouse was placed under a transparent glass funnel (18 cm
diameter, 15 cm-high) and the amount of time that the animal licked
the injected paw was monitored between 0 and 5 min (ﬁrst phase)
and 15 and 30 min (second phase) after the injection of formalin.
2.4. Evaluation of the nociceptive response of mice in the hot-plate model
A preliminary protocol was carried out to evaluate the latency for
the nociceptive behavior after exposing the mice on plate tempera-
tures of 50°, 52°, 54° or 56 °C. We selected the temperatures of 50 °C
(latency≈15 s) or 54 °C (latency≈8 s) to evaluate the effect induced
by nicotinamide in this model of nociceptive pain. One hour after
treatment with nicotinamide or dipyrone (positive control), each
animalwas placed on the heated (50 or 54 °C)metal plate. The latency
to lick one of the hind paws or to jump off plate was determined. The
animal was removed from the hot-plate immediately after the
response. The cut-off times were 30 or 50 s (temperatures of 54 or
50 °C, respectively) to avoid tissue damage.
2.5. Evaluation of the edema induced by carrageenan in rats or mice
Paw edema was measured with a plethysmometer (Model 7140,
Ugo Basile, Italy). The basal volume of the right hind paw was
measured before administration of any drug. After determination of
the basal volume, the animals were divided in the experimental
groups in such a way that the mean volumes of the different groups
were similar. Carrageenan was injected via the intraplantar (i.pl.)
route in rats (500 μg, 50 μl) or mice (600 μg, 30 μl). Considering that
(a) the paw volume was measured at 2, 4 and 6 h later, (b) the half-
life of nicotinamide may vary between 1 h (mice; Rojas et al., 1993)
and 5 h (rats; Petrack et al., 1966) and (c) preliminary results
indicated that only one dose of nicotinamide did not markedly inhibit
the response evaluated, we administered two doses of nicotinamide,
1 h before and 3 h after carrageenan. Similar protocol was used for
picolinamide. However, for isonicotinamide, only one dose, 1 h before
carrageenan, was used, as this was sufﬁcient to demonstrate the
investigated effect. The results were presented as the paw volume
variation in relation to the basal values.
2.6. Evaluation of the mechanical allodynia induced by carrageenan in
rats
Mechanical allodynia was measured with a 40 mN nylon ﬁlament
(Sorri, Brazil) as previously described (Souza et al., 2002). Brieﬂy, the
rats were kept individually in Perspex boxes (20×20 cm with 18 cm-
high walls) whose ﬂoor was a metal grid through which the ﬁlament
was pressed on the plantar surface of the right hind paw with the
strength just necessary to cause it to bend for approximately 1 s. The
number of withdrawal reﬂexes was determined in a trial of 10 touches
for each rat. The basal withdrawal frequency was determined before
administration of any drug. After determination of the basalwithdrawal
frequency, the animals were divided in the experimental groups in such
a way that the mean withdrawal frequencies of the different groups
were similar. The withdrawal frequency was measured at different
times after injection of the inﬂammatory stimulus. Nicotinamide was
administered 1 h before and 3 h after carrageenan.
2.7. Evaluation of the motor activity of mice
The motor activity of the animals was evaluated in a rota-rod
apparatus. The animals were trained on the apparatus for 3 days before
the experiment. On the experimental day, the animals were placed on a
rota-rod (14 rpm) and the time they spent on it wasmeasured. The cut-
off time was 2 min. After determination of the baseline values, the
animals were treatedwith nicotinamide, isonicotinamide, picolinamide
Fig. 3. Effect induced by nicotinamide (500 or 1000 mg/kg, p.o., −1 h) or dipyrone
(500 mg/kg, p.o.,−1 h) on the nociceptive response induced by heat (hot plate model,
50 °C) in mice. *** signiﬁcantly different from vehicle (Pb0.001). n=10.
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in the apparatus. In another protocol,we evaluated the effect inducedby
two administrations of nicotinamide to validate the results observed in
themodel ofmechanical allodynia. Theﬁrst administration occurred 3 h
before the ﬁrst evaluation of the motor activity. The second adminis-
tration occurred 1 h after the ﬁrst evaluation of themotor activity. After
the second administration, the motor activity was evaluated at 1 and
3 h.
2.8. Data collection and statistical analysis
Two observers evaluated the nociceptive behavior and edema in
the different experimental protocols. The observers were not aware of
the treatments and registered the nociceptive behavior or edema of
animals from the different experimental groups within each protocol.
The results, presented as mean±standard error mean (S.E.M.), were
analyzed by one-way analysis of variance followed by Newman–Keuls
post-hoc test when the main effect was signiﬁcant. A Pb0.05 was
considered signiﬁcant.
3. Results
Nicotinamide, at the doses of 125 or 250 mg/kg, did not inhibit the
nociceptive response induced by formalin in mice (data not shown).
However, in another protocol in which the doses of 500 or 1000 mg/kg
were used, we observed that the highest dose inhibited both phases of
nociceptive response (Fig. 2). Nicotinamide (1000 mg/kg) also in-
creased the latency for the nociceptive response in the hot-plate model
when a thermal stimulus of lower intensity (50 °C) was used (Fig. 3).
However,when a thermal stimulus of higher intensity (54 °C)was used,
the antinociceptive effect was not observed (Fig. 4). In both cases, an
increase of the latency for the nociceptive response was observed after
treatment of the animals with dipyrone (500 mg/kg). Nicotinamide
(500or 1000 mg/kg) also inhibited themechanical allodynia induced by
carrageenan in rats (Fig. 5).
To validate the results observed in the nociceptive models, we
investigated the effects inducedbynicotinamideon themotor coordina-
tion of the animals. A single dose of nicotinamide (1000 mg/kg,−1 h)
did not alter the time mice spent in the rota-rod apparatus. As
mentioned in the Materials and methods section, we also evaluated
the effect induced by two administrations of nicotinamide (500 or
1000 mg/kg). The ﬁrst administration occurred 3 h before and the
second administration occurred 1 h after the ﬁrst evaluation of the
motor activity. After the second administration, the motor activity was
evaluated at 1 and 3 h. In this protocol, we observed that while the
lowest dose did not alter the motor coordination of the animals, theFig. 2. Effect induced by nicotinamide (500 or 1000 mg/kg, p.o.,−1 h) on the nociceptive
response induced by formalin (2.5%; 20 μl; s.c.) in mice. * and *** signiﬁcantly different
from vehicle (Pb0.05 and Pb0.001, respectively). n=8.highest dose partially reduced this response 1 h after the second
administration. Such results validate the antinociceptive effect induced
by the lowest dose of nicotinamide. The positive control, phenobarbital
(50 mg/kg) markedly inhibited the performance of the animals
(Table 1).
In addition to inhibiting the nociceptive response, nicotinamide
(1000 mg/kg) also inhibited the paw edema induced by carrageenan
in mice (Fig. 6). Aiming to verify whether this inhibition also occurs in
other species, we observed that nicotinamide (1000 mg/kg) also
inhibits the inﬂammatory edema in rats (Fig. 7).
Next, we investigated whether the nicotinamide isomers, iso-
nicotinamide and picolinamide, also present similar activities.
Isonicotinamide (500 or 1000 mg/kg) inhibited the second phase of
nociceptive response induced by formalin in mice (Fig. 8). However,
when we evaluated the effects induced by picolinamide (500 or
1000 mg/kg), we observed lethality. Therefore, the doses were
reduced to 62.5 or 125 mg/kg. Information in the literature about
the lethal dose of the picolinamide was not found. Picolinamide
(125 mg/kg), inhibited the second phase of nociceptive response
induced by formalin in mice (Fig. 9).
To validate the results observed in the nociceptive models, we
investigated the effects induced by the nicotinamide isomers on the
motor coordination of mice. Isonicotinamide (500 or 1000 mg/kg) or
picolinamide (62.5 or 125 mg/kg) did not alter the time mice spent in
the rota-rod apparatus (Table 1).
In addition to inhibiting the nociceptive response, isonicotinamide
and picolinamide induced an anti-inﬂammatory effect in mice.
Isonicotinamide (1000 mg/kg), administered 1 h before carrageenan,
inhibited the paw edema at 2, 4 and 6 h (Fig. 10). Picolinamide
(125 mg/kg), administered 1 h before and 3 h after carrageenan,
inhibited the paw edema only at 6 h (Fig. 11).Fig. 4. Effect induced by nicotinamide (500 or 1000 mg/kg, p.o., −1 h) or dipyrone
(500 mg/kg, p.o.,−1 h) on the nociceptive response induced by heat (hot plate model,
54 °C) in mice. *** signiﬁcantly different from vehicle (Pb0.001). n=10.
Fig. 5. Effect induced by nicotinamide (500 or 1000 mg/kg, p.o., −1 h and 3 h) on
the mechanical allodynia induced by carrageenan (500 μg, 50 μl, i.pl.) in rats. * and
** signiﬁcantly different from vehicle (Pb0.05 and Pb0.01, respectively). n=8.
Fig. 6. Effect induced by nicotinamide (500 or 1000 mg/kg, p.o., −1 h and 3 h) on the
edema induced by carrageenan inmice. The basal paw volumes of the groups treatedwith
vehicle, nicotinamide 500 and nicotinamide 1000 were 102±4, 102±2 and 103±3 μl,
respectively. *, ** and *** signiﬁcantly different fromvehicle (Pb0.05, Pb0.01 and Pb0.001,
respectively). n=8.
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We initially observed that nicotinamide inhibited the nociceptive
response induced by formalin, an experimental model of nociceptive
and inﬂammatory pain. Theﬁrst phase, that starts immediately after the
injection of formalin, has been attributed to direct activation by
formaldehyde of transient receptor potential (TRP) channels, speciﬁ-
cally TRPA1 (McNamara et al., 2007) and TRPV1 (Tian et al., 2009), in
nociceptors. The late phase starts approximately 15 min after formalin
injection and is associated with the development of an inﬂammatory
response at the injection site that contributes to the activation or
sensitization of nociceptors and changes in the excitability of dorsal
horn neurons (Tjolsen et al., 1992). Although nicotinamide inhibited
bothphases of the nociceptive response, the secondphasewas inhibited
to a greater extent indicating a proﬁle similar to that of anti-
inﬂammatory drugs. It is well established that anti-inﬂammatory
drugs markedly inhibit the second phase of the nociceptive response
induced by formalin, while exert little or no effect on the ﬁrst phase
(Hunskaar and Hole, 1987). It has been shown that nicotinamide
inhibits the production of cytokines (Ungerstedt et al., 2003),
prostaglandin (PG) E2 (Cuzzocrea et al., 1999b) and nitric oxide (NO)
(Kao et al., 2007), inﬂammatory mediators that may contribute to the
secondphase of the nociceptive response induced by formalin.Whether
the inhibitory effect induced by nicotinamide on the production of
inﬂammatorymediators results from inhibition of PARP-1 is not known.
However, a connection between the antinociceptive effect induced by
nicotinamide in the formalinmodel with PARP-1 inhibition is attractiveTable 1
Effect induced by nicotinamide (500 or 1000 mg/kg, p.o., −1 h or −1 h and 3 h),
isonicotinamide (1000 mg/kg, p.o., −1 h), picolinamide (125 mg/kg, p.o., −1 h) or
phenobarbital (50 mg/kg, p.o., −1 h) on the time spent by mice on the rotating rod.
Treatment Time spent on the rotating rod (s)
Baseline 1 h
Vehicle 118±2 119±1
Nicotinamide 1000 120±0 120±0
Isonicotinamide 1000 120±0 120±0
Picolinamide 125 118±2 120±0
Phenobarbital 50 120±0 15±4a
Baseline 2 h 4 h 6 h
Vehicle 120±0 120±0 120±0 120±0
Nicotinamide 500 120±0 120±0 120±0 120±0
Nicotinamide 1000 120±0 120±0 66±18b 95±15
a,b signiﬁcantly different from respective vehicle-treated group at the same time point
(Pb0.001). n=8.as it has been recently demonstrated that formaldehyde activates this
enzyme in cell cultures (Lim et al., 2010).
Nicotinamide also inhibited the mechanical allodynia and edema
induced by carrageenan. These responses result from the action of
many inﬂammatory mediators such as NO (Handy and Moore, 1998;
Nakamura et al., 1996), eicosanoids (Tonussi and Ferreira, 1994;Vinegar
et al., 1987), and cytokines (Chen et al., 1994; Cunha et al., 2000), among
others. Moreover, local neutrophil inﬁltration and activation also
contribute to the response induced by carrageenan (Salvemini et al.,
1996) by producing chemokines, cytokines, NO and reactive oxygen
species. As it has been demonstrated that carrageenan increases the
stainingof PARP-1 (Cuzzocrea et al., 2004) andnicotinamide inhibits the
activity of this enzyme (Radons et al., 1994; Uchigata et al., 1982), it is
tempting to associate this last effect with the inhibition of carrageenan-
induced responses. It has been shown that PARP-1 inhibitors, including
nicotinamide, may inhibit the production of many inﬂammatory
mediators that contribute to the mechanical allodynia and edema
induced by carrageenan. Cuzzocrea et al. (1999b) demonstrated that
two PARP-1 inhibitors, nicotinamide and 3-aminobenzamide, inhibit
the production of PGE2 and leukocyte migration in a model of pleurisy
induced by carrageenan. Some studies demonstrated that nicotinamide
decreases the activation of NF-kB (Crowley et al., 2000; Grange et al.,
2009; Pero et al., 1999) and the production of inﬂammatory cytokines
such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α (FukuzawaFig. 7. Effect induced by nicotinamide (500 or 1000 mg/kg, p.o., −1 h and 3 h) on the
edema induced by carrageenan in rats. The basal paw volumes of the groups treated
with vehicle, nicotinamide 500 and nicotinamide 1000 were 1.16±0.08, 1.16±0.06
and 1.15±0.04 ml, respectively. *, ** and *** signiﬁcantly different from vehicle
(Pb0.05, Pb0.01 and Pb0.001, respectively). n=6.
Fig. 8. Effect induced by isonicotinamide (500 or 1000 mg/kg, p.o., −1 h) on the
nociceptive response induced by formalin (2.5%; 20 μl; s.c.) in mice. * and ** signiﬁcantly
different from vehicle (Pb0.05 and Pb0.01, respectively). n=8.
Fig. 10. Effect induced by isonicotinamide (500 or 1000 mg/kg, p.o.,−1 h) on the edema
induced by carrageenan inmice. Thebasal pawvolumes of the groups treatedwith vehicle,
isonicotinamide 500 and isonicotinamide 1000 were 89±2, 88±2 and 87±2 μl,
respectively. * and ** signiﬁcantly different from vehicle (Pb0.05 and Pb0.01,
respectively). n=8.
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such as PGE2 (Cuzzocrea et al., 1999b). Oliver et al. (1999) provided
further support for the inﬂammatory role of PARP-1 by demonstrating
that PARP-1-deﬁcient mice have reduced expression of NF-kB,
decreased production of cytokines and other inﬂammatory mediators
such as NO, TNF-α and IFN-γ.
Although amarked inhibition of the second phase of the nociceptive
response induced formalin and also the mechanical allodynia and
edema induced by carrageenan in animals previously treated with
nicotinamide is suggestive of an anti-inﬂammatory proﬁle, this drug
also inhibited the response in an experimental model of nociceptive
pain induced by heat. As the nociceptive response in this model is
immediate (few seconds), it is highly unlikely that the effect induced by
nicotinamide results from inhibition of PARP-1 or reduced productionof
inﬂammatory mediators. Inhibition of such immediate response would
likely be associated with direct inhibition of neuronal excitability.
Although there is scarce data on the effect induced by nicotinamide on
neuronal excitability, it has been recently demonstrated that NAD+,
whichmay be derived from nicotinamide (Ijichi et al., 1966), activates a
class of sodium-activated potassium channels, Slack KNa (Tamsett et al.,
2009). These channels may have a role in nociceptors excitability as it
has been suggested that they regulate dorsal root ganglion (DRG)
neuronal resting membrane potential (Bischoff et al., 1998). Curiously,
an anti-inﬂammatory drug with analgesic activity, niﬂumic acid,
activates this class of KNa channels (Dai et al., 2010). In addition, protein
kinase A, an enzyme activated by many inﬂammatory mediators,
induces the internalization of these channels and increases DRG neuron
excitability (Nuwer et al., 2010). Modulation of TRPV1 and Nav1.8
sodium channels, important targets in the nociceptive processing
pathways (Jara-Oseguera et al., 2008; Mathie, 2010; Villareal et al.,
2009), by nicotinamide and its isomers may also be indicated as aFig. 9. Effect induced by picolinamide (62.5 or 125 mg/kg, p.o.,−1 h) on the nociceptive
response induced by formalin (2.5%; 20 μl; s.c.) in mice. * signiﬁcantly different from
vehicle (Pb0.05). n=8.possibility. It has been shown that some nicotinamide derivatives,
although very distinct from the parent compound, act as TRPV1
(Westaway et al., 2008) or Nav1.8 sodium channels (Kort et al., 2010)
antagonists.
The effect induced by nicotinamide in the hot-plate model varied
according to the intensity of the thermal stimulus as it increased the
latency for the nociceptive response when the mice were exposed to a
low (50 °C), but not to a high (54 °C) temperature. This proﬁle has also
been demonstrated for other drugs. The antinociceptive effect induced
by some opioid analgesics, such as buprenorphine and dezocine, is
observed at the temperature of 53° but not at 56 °C (Fischer et al., 2008).
These results conﬁrm the probability of demonstrating the antinoci-
ceptive activity of a drug in an experimental model of nociceptive pain
when using a thermal stimulus of lower intensity (Plone et al., 1996). It
can behypothesized that temperatures of 50 and54 °C activate different
nociceptive mechanisms that are differently affected by many drugs,
including opioids (Fischer et al., 2008) and nicotinamide. Providing
support to this possibility, Caterina et al. (1997, 1999) have shown that
temperatures above 43 °C activate TRPV1 channels in sensory neurons,
while temperatures superior to 52 °C are necessary to activate TRPV2
channels.
The effect induced by nicotinamide on the performance of the
animals on the rotating rod was also evaluated to determine whether
the effects observed in the experimental models of pain represent a
genuine antinociceptive effect of nicotinamide itself without confound-
ing effect on motor coordination or muscle tone. This is important as itFig. 11. Effect induced by picolinamide (62.5 or 125 mg/kg, p.o., -1 h and 3 h) on the
edema induced by carrageenan inmice. The basal paw volumes of the groups treatedwith
vehicle, picolinamide 62.5 and picolinamide 125 were 105±3, 103±4 and 105±3 μl,
respectively. ** signiﬁcantly different from vehicle (Pb0.01). n=8.
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pentylenetetrazole or kynurenine, suggestinga central depressant effect
(Lapin, 1981). However, nicotinamide and its isomers, administered at
single doses, did not alter the motor coordination of the animals. Only
the highest dose (1000 mg/kg) of nicotinamide, administered twice 3 h
apart, partially inhibited themotor coordination. Thus, it is unlikely that
nicotinamide inhibition of the nociceptive behavior evaluated in the
different experimental models is due to motor incoordination or a
muscle relaxing effect.
Although we did not determine the plasma concentrations of
nicotinamide in the experimental animals, it is possible that they
correlate with the concentrations that inhibit the production of
inﬂammatory mediators or enzyme activity in vitro. Ungerstedt et al.
(2003) showed that concentrations of nicotinamide that inhibit
cytokine production or PARP-1 activity in vitro vary from 2 to
40 mmol/l (244 to 4880 μg/ml). Rojas et al. (1993) demonstrated that
intraperitoneal administration of nicotinamide (500 mg/kg) resulted
in plasma concentrations of 3.67 mmol/l (448 μg/ml). As nicotinamide
is well absorbed, it is expected that its plasma concentrations in mice
and rats after per os administration of doses of 500 or 1000 mg/kg are
within the range of concentrations that inhibit the production of
inﬂammatory cytokines or PARP-1 activity.
The antinociceptive activity of nicotinamide is in line with the
demonstration of its beneﬁcial effects in patients with rheumatoid
arthritis. Hoffer (1959) showed that doses varying from 900 to
4000 mg per day improved joint function of the patients by
decreasing joint stiffness, edema, deformity and pain. The doses
(500 and 1000 mg/kg) of nicotinamide that induced antinociceptive
and anti-inﬂammatory effects in mice and rats ﬁt with those used in
human studies when the formula for dose translation based on body
surface area is applied (Reagan-Shaw et al., 2008).
Although our results clearly demonstrate marked antinociceptive
and anti-inﬂammatory effects induced by nicotinamide, a limitation
of the study refers to the administration of the compound before the
injection of the inﬂammatory stimuli. In a typical clinical use, anti-
inﬂammatory drugs are administered after pain and inﬂammation is
present. It has been shown that anti-inﬂammatory drugs more
efﬁciently prevent than reverse the inﬂammatory edema in experi-
mental models (Zhang et al., 1997). Thus, to fully appreciate the
potential of nicotinamide as an anti-inﬂammatory, it should be
administered after the induction of the inﬂammatory response.
However, the beneﬁcial effects induced by nicotinamide in patients
with established rheumatoid arthritis (Hoffer, 1959) provide support
to the potential anti-inﬂammatory activity of this compound.
As it has been demonstrated that the nicotinamide isomers,
picolinamide and isonicotinamide, also inhibit PARP-1 (Itoh et al.,
1984; Uchigata et al., 1982), it was not surprising to observe that both
also inhibited the second phase of the nociceptive response induced
by formalin and the paw edema induced by carrageenan. Similarly to
what was observed for nicotinamide, the isomers induced an
antinociceptive effect that was not associated with motor incoordi-
nation. Although nicotinamide and its isomers inhibit PARP-1,
physical–chemical analysis demonstrated that they differ in their
steric and electrostatic interactions (Borba et al., 2008; Seliger and
Zagar, 2008) which may contribute to different biological activities,
such as the lethality induced by higher doses of picolinamide, the
isomer that possesses the side chain in the ortho position of pyridine
ring. Regarding nicotinamide toxicity, it was demonstrated that the
LD50 for mice is 4.5 g/kg after p.o. administration (Hoffer, 1967). No
information is available about toxicity of the nicotinamide isomers,
isonicotinamide and picolinamide. Although the isomers of nicotin-
amide, picolinamide and isonicotinamide, are not precursors of
NAD+, the inhibition of PARP-1 induced by these compounds can
contribute to the maintenance of adequate concentrations of this
coenzyme. Thus, nicotinamide and its isomersmay differ in relation to
the mechanisms that contribute to the maintenance of adequatelevels of NAD+, in other words, nicotinamide might act in direct and
indirect ways, while the isomers would act indirectly.
Concluding, our results represent the ﬁrst demonstration of the
activity of nicotinamide in different experimentalmodels of nociceptive
and inﬂammatory pain and also provide further support to its anti-
inﬂammatory activity. The nicotinamide isomers, picolinamide and
isonicotinamide, also present similar activities. The demonstration of
new activities for nicotinamide is important as it may contribute to
expand its use in the treatment of other pathological conditions. This is
particularly relevant as nicotinamide has already been approved for
clinical use and experience to date suggests that the ratio of risk to
beneﬁt of its long-term use would be highly favorable.
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